Effects of systemic inflammation on relapse in early breast cancer

Autor: Nicholas P. McAndrew, Lisa Bottalico, Tapan Ganguly, Angela DeMichele, Jennifer Marie Rosado, Jun J. Mao, Clementina Mesaros, Patricia Y. Tsao, Ian A. Blair, Sarah J. Song, Phyllis A. Gimotty
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
medicine.medical_specialty
Aging
medicine.drug_class
Inflammation
Systemic inflammation
Article
03 medical and health sciences
Prognostic markers
0302 clinical medicine
Breast cancer
Clinical Research
Internal medicine
Genotype
Breast Cancer
medicine
Genetics
2.1 Biological and endogenous factors
Pharmacology (medical)
Radiology
Nuclear Medicine and imaging
Serum amyloid A
Aromatase
Aetiology
skin and connective tissue diseases
RC254-282
Cancer
screening and diagnosis
biology
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Estrogen
4.1 Discovery and preclinical testing of markers and technologies
Detection
030104 developmental biology
Hormone receptor
5.1 Pharmaceuticals
030220 oncology & carcinogenesis
biology.protein
medicine.symptom
Development of treatments and therapeutic interventions
business
Zdroj: NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
NPJ breast cancer, vol 7, iss 1
ISSN: 2374-4677
Popis: Chronic inflammation has been a proposed mechanism of resistance to aromatase inhibitors in breast cancer. Stratifying by HER2 status, a matched case-control study from the Wellness After Breast Cancer-II cohort was performed to assess whether or not elevated serum inflammatory biomarkers (C-Reactive protein [CRP], interleukin-6 [IL-6], and serum amyloid A [SAA]) and/or the presence of a high-risk IL-6 promoter genotype were associated with recurrence of hormone receptor positive (HR+) early breast cancer. Estrogen levels were also measured and correlated with biomarkers and disease outcomes. CRP and SAA were significantly associated with an increased risk of recurrence in the HR+/HER2− group, but not the HR+/HER2+ group. Mean serum estrogen levels were non-significantly elevated in patients who relapsed vs. non-relapsed patients. Surprisingly, high-risk IL-6 promoter polymorphisms were strongly associated with HER2+ breast cancer relapse, which has potential therapeutic implications, as elevated intracellular IL-6 has been associated with trastuzumab resistance in pre-clinical models.
Databáze: OpenAIRE
Externí odkaz: